467 days. That’s the patent term adjustment — PTA — that pushed Allergan’s U.S. Patent 7,741,356 to expire on June 24, 2026, well past its family siblings.
And yesterday, the CAFC said: hands off. That first-filed, first-issued claim survives obviousness-type double patenting — ODP — attacks from later-filed, earlier-expiring references sharing the same priority date.
Look, in the gritty world of pharma IP battles, where exclusivity means billions — eluxadoline raked in over $200 million peak sales for IBS-D treatment — this ruling isn’t just legalese. It’s a shield for parent patents that dared to snag extra PTA days during prosecution delays.
“To hold otherwise—that a first-filed, first-issued parent patent having duly received PTA can be invalidated by a later-filed, later-issued child patent with less, if any, PTA—would not only run afoul of the fundamental purposes of ODP, but effectively abrogate the benefit Congress intended to bestow on patentees when codifying PTA.” – CAFC opinion
Judge Lourie — same guy who penned Cellect — drops this mic-drop quote, flipping the script on Sun Pharma’s invalidity bid.
Why Cellect Didn’t Seal Allergan’s Fate
Cellect was the boogeyman here. Back in 2023, it hammered home that PTA-adjusted expiration dates rule ODP analyses, dooming later-expiring claims to terminal disclaimers regardless.
But here’s the pivot — and my bet, the insight Cellect’s authors didn’t fully telegraph: filing and issuance order matters when the reference claims come later. Sun’s arsenal? Claim 33 of the ‘011 patent and claim 5 of the ‘709, both filed after, issued after Allergan’s ‘356 parent.
The district court in Delaware shrugged that off. “Expiration dates only,” they said, citing Cellect like gospel, invalidating claim 40 of the ‘356. CAFC? Nope. Cellect tackled whether claims with PTE/PTA can reference others — not this upside-down scenario where kids try to kill the parent.
Short para for punch: Parents win.
Delaware also tanked four Allergan continuations under §112 written description. CAFC swats that too — priority claims hold, species-genus support intact for eluxadoline formulations.
Sun leaned hard on Gilead from 2014, where a later-issued but earlier-expiring patent zapped an earlier-issued longer one. Fair play — on its face, it stings. But CAFC slices fine: Gilead lacked the ‘356’s first-to-file, first-to-issue primacy. No shared priority chain flipping the script.
Does This Greenlight Risky Patent Families for Pharma?
Pharma’s playbook just thickened. Think about it — drug patents aren’t filed in a vacuum. A priority provisional spawns divisionals, continuations, chasing broader claims or dodging rejections.
Allergan’s family tree: ‘356 as the trunk, claiming eluxadoline tablets first (filed 2005, issued 2010). Kids like ‘011 (filed 2012, issued 2021) narrow to specific doses, but expire sooner sans PTA luck.
Pre-Allergan, generics like Sun could cherry-pick: use a short-lived child to ODP-kill the long-living parent, unlocking markets years early. Now? That gambit fizzles if you’re not first-in-line.
My unique angle — and it’s not in the opinion: this echoes the 1995 Uruguay Round GATT shift, when Congress baked in 20-year terms and PTA to fix PTO delays. Back then, double patenting was judge-made chaos; today, CAFC’s guarding that congressional gift against judicial overreach. Bold prediction: expect a 20-30% uptick in broad parent filings, with pharma banking on PTA windfalls to anchor families. Sun’s loss? A win for incumbents holding $100B+ in U.S. drug exclusivity.
But — em-dash alert — don’t pop champagne yet. Dissent from Judge Dyk flags risks: could this spawn unjust extensions? Nah. ODP’s core — no double-dipping indistinct claims — stays ironclad. Just no fratricide from junior sibs.
Market ripple? Eluxadoline’s off-patent soon-ish (2026), but for Allergan’s pipeline — or AbbVie’s, post-acquisition — this cements defense. Sun’s ANDA challenge stalls; generics wait longer.
And the §112 reversal? Delaware demanded every species in the ‘356 genus for support. CAFC: written description flexes for predictable arts like tablets. Predictable? Pharma chemists snicker, but hey, Lourie’s call.
How Gilead Survives (Barely)
Sun’s Gilead crutch — 753 F.3d 1208 — let a later-issued early-expirer invalidate. CAFC nods: sure, but no first-filed shield there. Here, ‘356 predates, shares priority, issues first. Gilead’s ghost lives, just doesn’t haunt parents.
One sentence wonder: Stability reigns.
Zoom out to data: USPTO stats show PTA averaging 400-500 days for pharma apps (per 2023 report). That’s 1.3 years extra — gold for blockbusters. This ruling? Locks it in for family elders.
Critique the spin — Sun’s PR paints this as loophole chaos. Please. It’s fidelity to statute, not hype.
Wrapping the weave: CAFC restores order to ODP’s judicial thicket, prioritizing sequence over pure expiration math. Patentees breathe; challengers recalibrate.
**
🧬 Related Insights
- Read more: Data-Driven Pricing: Retail’s AI Edge or Consumer Trap?
- Read more: Project Nimbus: Google and Amazon See the Risks, Shrug Them Off
Frequently Asked Questions**
What is obviousness-type double patenting?
ODP is a judge-made bar preventing multiple patents on indistinct inventions to extend exclusivity beyond the first patent’s term.
Does PTA protect parent patents from ODP?
Yes, per CAFC in Allergan: first-filed, first-issued parents with PTA can’t be invalidated by later family claims.
How does this affect generic drug challenges?
Generics lose a weapon against long-expiring parents in patent families, potentially delaying market entry.
